|
|||||
|
|
| 恩替卡韦治疗45例慢性乙型重型病毒性肝炎的疗效观察 | |
| 引用本文： | 彭翠君,廖文秋,钟鹰.恩替卡韦治疗45例慢性乙型重型病毒性肝炎的疗效观察[J].现代生物医学进展,2010,10(24). |
| 作者姓名： | 彭翠君 廖文秋 钟鹰 |
| 作者单位： | 1. 桑植县人民医院传染科,湖南,桑植,427100 2. 南华大学附属第二医院消化内科,湖南,衡阳,421001 3. 湘潭市第一人民医院消化内科,湖南,湘潭,411100 |
| 摘 要： | 目的:评价恩替卡韦治疗慢性乙型重型病毒性肝炎的临床疗效。方法:45例患者在常规治疗的基础上给予恩替卡韦0.5mg,每日1次口服;另47例给予拉米夫定100mg,每日1次口服,存活患者的治疗时间不少于6个月。结果:恩替卡韦组临床疗效总有效率为80.0%,显著高于拉米夫定组总有效率66.0%(P<0.05);总胆红素(TBIL)和谷丙转氨酶(ALT)分别由治疗前的378.2±36.3umol/L和546.8±56.5 U/L降至146.5±35.4μmol/L和46.5±21.5U/L,凝血酶原活动度(PTA)由治疗前的32.5±5.8%升至59.5±16.8%,均较拉米夫定组改善明显(P<0.05);恩替卡韦组的HBeAg和HBV-DNA转阴率分别为71.4和66.7%,明显高于拉米夫定组的47.6%和45.2%(P<0.05)。病死率分别为6.7%和10.6%,无显著性差异(P>0.05)。结论:恩替卡韦治疗慢性乙型重型肝炎患者在临床疗效、肝功能改善和抑制病毒复制方面均优于拉米夫定治疗者。 |
| 关 键 词： | 慢性乙型重型病毒性肝炎 恩替卡韦 拉米夫定 |
Entecavir for chronic severe viral hepatitis B:clinical observation of 45 cases |
|
| PENG Cui-jun,LIAO Wen-qiu,ZHONG Ying.Entecavir for chronic severe viral hepatitis B:clinical observation of 45 cases[J].Progress in Modern Biomedicine,2010,10(24). | |
| Authors: | PENG Cui-jun LIAO Wen-qiu ZHONG Ying |
| Affiliation: | PENG Cui-jun1,LIAO Wen-qiu2,ZHONG Ying3(1 The Sangzhi County People's Hospital,Hunan,427100,China,2 The Second Affiliated Hospital of South china University,Hengyang,Hunan 421001,3 Xiangtan City First People Hospital,411100) |
| Abstract: | Objective: To evaluate the clinical effect of entecavir(ETV)in the treatment for patients with chronic severe hepatitis B.Methods: Forty-five patients with chronic severe hepatitis B were treated with entecavir(ETV) at dose of 0.5 mg daily besides conven-tional therapy for at least 6 months,while Forty-seven patients were treated with lamivudine(LVD)100 mg as the control group.Results: The entecavir clinical efficacy of the total effective rate was 80.0%,significantly higher than the lamivudine group,the to... |
| Keywords: | Hepatitis B Entecavir Lamivudine |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |
